Conference Coverage
about 1 month ago
ASCO 2026: 3 key themes shaping the future of GU oncologyabout 2 months ago
Alan Bryce, MD, highlights key phase 3 advances in prostate cancerLatest News
Sep 29, 2026 | News
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
Armine K. Smith, MD, on addressing sexual health in modern bladder cancer care
Sep 29, 2026
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
Sep 28, 2026
A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancer
Sep 28, 2026
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
Sep 28, 2026
Advertisement
Shorts
0:28
What policymakers must do to preserve patient choice
2 hours ago
by
Celeste Kirschner, CAE, MHSA
1:14
Why the bladder diary matters in nocturia workup
a day ago
by
Kari A.O. Tikkinen, MD, PhD
0:50
3 actionable steps to improve PSMA-PET access
4 days ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:23
Site-neutral payment and the future of community urology
5 days ago
by
Celeste Kirschner, CAE, MHSA
0:51
Reassessing goals of care throughout cancer treatment
6 days ago
by
Mary Dunn, MSN, RN, NP-C, OCN
1:17
Neoadjuvant therapy before prostatectomy: Assessing functional outcomes
7 days ago
by
Adam B. Weiner, MD(+1 more)
0:40
How unequal PSMA-PET access may affect prostate cancer care
8 days ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:33
What a positive NeoBLAST trial would mean for MIBC care
11 days ago
by
Marie-Pier St-Laurent, MD, FRCSC
0:43
Why independent urology practices face growing pressure
12 days ago
by
Celeste Kirschner, CAE, MHSA
1:33
The long-term cost question behind OAB drug selection
13 days ago
by
Anjali Kapur, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
Published: | Updated:
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Advertisement
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
Advertisement
Advertisement
Trending on Urology Times
1
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
2
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
3
A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancer
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5